1. Boulaiz H, Alvarez PJ, Ramirez A, Marchal JA, Prados J, Rodríguez-Serrano F, et al. Nanomedicine: Application areas and development prospects. Int J Mol Sci. 2011; 12(5): 3303-21.

2. Vauthey S, Santoso S, Gong H, Watson N, Zhang S. Molecular self-assembly of surfactant-like peptides to form nanotubes and nanovesicles. Proceed National Acad Sci. 2002 ; 99(8): 5355-60.

3. Wang ZL. Nanobelts, nanowires, and nanodiskettes of semiconducting oxides—from materials to nanodevices. Adv Mater. 2003; 15(5): 432-6.

4. Mozafari RM. Nanoliposomes: from fundamentals to recent developments: Trafford Publishing, 2005, 238 pages.

5. Misra R, Sahoo SK. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci. 2010 ;39(1): 152-63.

6. Hughes GA. Nanostructure-mediated drug delivery. Nanomedicine: Nanotechnology, Biology and Med. 2005;1(1):22-30.

7. Akbari V, Abedi D, Pardakhty A, Sadeghi-Aliabadi H. Ciprofloxacin nano-niosomes for targeting intracellular infections: an in vitro evaluation. J Nanoparticle Res. 2013 ;15(4): 1-14.

8. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 2010; 141(1): 13-21.

9. Sennato S, Bordi F, Cametti C, Marianecci C, Carafa M, Cametti M. Hybrid niosome complexation in the presence of oppositely charged polyions. J Phys Chem B. 2008 ;112: 3707-20.

10. Hanjani-Vila R, Rondot B, Vanlerberghie G. Dispersion of lamellar phases of non-ionic lipids in cosmetic products. Int J Cosmet Sci. 1979; 1(5): 303-14.

11. Fang JY, Hong CT, Chiu WT, Wang YY. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm. 2001 ;219(1-2): 61-72.

12. Ijeoma F, Vyas S. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172(1): 33.

13. Sahin NO. Niosomes as nanocarrier systems. Nanomat Nanosys Biomed Appl. 2007 :67-81.

14. Fang J-Y, Yu S-Y, Wu P-C, Huang Y-B, Tsai Y-H. In vitro skin permeation of estradiol from various proniosome formulations. Int J Pharm. 2001; 215(1): 91-9.

15. Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int J Pharm. 1999 ;185(1): 23-35.

16. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998; 172(1): 33-70.

17. Sezgin-Bayindir Z, Yuksel N. Investigation of Formulation Variables and Excipient Interaction on the Production of Niosomes. AAPS PharmSciTech. 2012: 1-10.

18. Varshosaz J, Pardakhty A, Hajhashemi V, Najafabadi A. Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Del. 2003 ;10: 251-62.

19. Okahata Y, Ando R, Kunitake T. Phase Transition of the Bilayer Membrane of Synthetic Dialkyl Amphiphiles as Studied by Differential Scanning Calorimetry. Berichte der Bunsengesellschaft für physikalische Chemie. 1981 ;85(8): 789-98.

20. Jain C, Vyas S. Preparation and characterization of niosomes containing rifampicin for lung targeting. J  Microencap. 1995; 12: 401-7.

21. Jain S, Singh P, Mishra V, Vyas S. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B. Immunol Lett. 2005; 101: 41-9.

22. Yoshioka T, Sternberg B, Florence A. Preparation and properties of vesicles (niosomes)of sorbitan monoesters (Span 20, 40, 60, and 80) and a sorbitan triester (Span 85). Int J Pharm. 1994 ;105: 1-6.

23. Zarif L, Gulik-Krzywicki T, Riess JG, Pucci B, Guedj C, Pavia AA. Alkyl and perfluoroalkyl glycolipid-based supramolecular assemblies. Colloid Surf A: Physicochem Eng Aspect. 1994 ;84(1): 107-12.

24. Echegoyen LE, Hernandez JC, Kaifer AE, Gokel GW, Echegoyen L. Aggregation of steroidal lariat ethers: the first example of nonionic liposomes (niosomes) formed from neutral crown ether compounds. J Chem Soc, Chem Commun. 1988 (12): 836-7.

25. Junyaprasert V, Teeranachaideekul V, Supaperm T. Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS PharmSciTech. 2008 ;9: 851-9.

26. Devaraj G, Parakh S, Devraj R, Apte S, Rao B, Rambhau D. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci. 2002 ;251: 360-5.

27. Masotti A, Vicennati P, Alisi A, Marianecci C, Rinaldi F, Carafa M, et al. Novel Tween® 20 derivatives enable the formation of efficient pH-sensitive drug delivery vehicles for human hepatoblastoma. Bioorg Med Chem Lett. 2010 ;20(10): 3021-5.

28. Nasseri B. Effect of cholesterol and temperature on the elastic properties of niosomal membranes. Int J Pharm. 2005 ;300: 95-101.

29. Caracciolo G, Pozzi D, Caminiti R, Marianecci C, Moglioni S, Carafa M, et al. Effect of hydration on the structure of solid-supported Niosomal membranes investigated by in situ energy dispersive X-ray diffraction. Chem Phys Lett. 2008 ;462(4-6): 307-12.

30. van Hal DA, Bouwstra JA, van Rensen A, Jeremiasse E, de Vringer T, Junginger HE. Preparation and characterization of nonionic surfactant vesicles. J Colloid Interface Sci. 1996 ;178(1): 263-73.

31. Chen H, Zhu H, Zheng J, Mou D, Wan J, Zhang J, et al. Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin. J Control Release. 2009 ;139(1): 63-72.

32. Pardakhty A, Shakibaie M, Daneshvar H, Khamesipour A, Mohammadi-Khorsand T, Forootanfar H. Preparation and evaluation of niosomes containing autoclaved Leishmania major: a preliminary study. J Microencapsul. 2012 ;29(3): 219-24.

33. Uchegbu IF, Duncan R. Niosomes containing N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin (PK1): effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution. Int J Pharm. 1997;155(1):7-17.

34. Uchegbu I, Double J, Kelland L, Turton J, Florence A. The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models. J Drug Target. 1996 ;3: 399-409.

35.      Dimitrijevic D, Lamandin C, Uchegbu IF, Shaw AJ, Florence AT. The effect of monomers and micellar and vesicular forms of non-ionic surfactants (Solulan C24 and Solulan 16) on Caco-2 cell monolayers. J Pharm Pharmacol. 1997; 49(6): 611-6.

36. Suwakul W, Ongpipattanakul B, Vardhanabhuti N. Preparation and characterization of propylthiouracil niosomes. J Liposome Res. 2006 ;16(4): 391-401.

37. Yang D, Zhu J, Huang Z, Ren H, Zheng Z. Synthesis and application of poly (ethylene glycol)-cholesterol (Chol-PEGm) conjugates in physicochemical characterization of nonionic surfactant vesicles. Colloid Surf B: Biointerfaces. 2008; 63(2): 192-9.

38. Pardakhty A, Moazeni E, Varshosaz J, Hajhashemi V, Najafabadi AR. Pharmacokinetic study of niosome-loaded insulin in diabetic rats. DARU J Pharm Sci. 2012 ;19(6): 404-11.

39. Balasubramaniam A, Kumar V, Pillai K. Formulation and in vivo evaluation of niosome-encapsulated daunorubicin hydrochloride. Drug Dev Ind Pharm. 2002 ;28 :1181-93.

40. Rogerson A, Cummings J, Florence A. Adriamycin-loaded niosomes: drug entrapment, stability and release. J  Microencap. 1987 ;4: 321-8.

41. Kirby C, Gregoriadis G. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Nat Biotechnol. 1984 ;2(11): 979-84.

42. Foster T, Dorfman KD, Ted Davis H. Giant biocompatible and biodegradable PEG–PMCL vesicles and microcapsules by solvent evaporation from double emulsion droplets. J Colloid Interface Sci. 2010 ;351(1): 140-50.

43. Zidan AS, Rahman Z, Khan MA. Product and process understanding of a novel pediatric anti-HIV tenofovir niosomes with a high-pressure homogenizer. Eur J Pharm Sci. 2011 ;44(1): 93-102.

44. Liu T, Guo R. Structure and transformation of the niosome prepared from PEG 6000/Tween 80/Span 80/H2O lamellar liquid crystal. Colloid Surf A: Physicochem Eng Aspect. 2007 ;295(1): 130-4.

45. Nademi M, Mozaffari A, Farrokhabadi A. A New Self Healing Method in Composite Laminates Using the Hollow Glass Fiber. Key Eng Mat. 2011 ;471: 548-51.

46. Manosroi A, Chutoprapat R, Abe M, Manosroi J. Characteristics of niosomes prepared by supercritical carbon dioxide (scCO2) fluid. Int J Pharm. 2008; 352: 248-55.

47. Talsma H, Steenbergen Mv, Borchert J, Crommelin D. A novel technique for the one-step preparation of liposomes and nonionic surfactant vesicles without the use of organic solvents. Liposome formation in a continuous gas stream: the 'bubble' method. J Pharm Sci. 1994 ;83 :276-80.

48. Lo C, Jahn A, Locascio L, Vreeland W. Controlled self-assembly of monodisperse niosomes by microfluidic hydrodynamic focusing. Langmuir. 2010 ;26: 8559-66.

49. Okumura Y, Iwata Y. Electroformation of Giant Vesicles and Electrode Polarity. Bull Chem Soc Jpn. 2011; 84(10): 1147-9.

50. Jin Y, Wen J, Garg S, Liu D, Zhou Y, Teng L, et al. Development of a novel niosomal system for oral delivery of Ginkgo biloba extract. Int J Nanomedicine. 2013 ;8: 421.

51. Di Marzio L, Esposito S, Federica R, Carlotta M, Maria C. Polysorbate 20 vesicles as oral delivery system: in-vitro characterization. Colloid Surf B: Biointerfaces. 2012 ;104: 200-6.

52. O’brien M, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 ;15(3): 440-9.

53. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res. 2009 ;15(6): 1973-80.

54. Cosco D, Paolino D, Muzzalupo R, Celia C, Citraro R, Caponio D, et al. Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil. Biomed Microdevice. 2009 ;11(5): 1115-25.

55. Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, et al. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer. Ann Oncol. 2002; 13(6): 910-8.

56. Tavano L, Vivacqua M, Carito V, Muzzalupo R, Caroleo MC, Nicoletta F. Doxorubicin loaded magneto-niosomes for targeted drug delivery. Colloid Surf B: Biointerfaces. 2013 ;102: 803-7.

57. Shi B, Fang C, Pei Y. Stealth PEG PHDCA niosomes: Effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J Pharm Sci. 2006 ;95(9): 1873-87.

58. Hashim F, El-Ridy M, Nasr M, Abdallah Y. Preparation and characterization of niosomes containing ribavirin for liver targeting. Drug Del. 2010 ;17(5): 282-7.

59. Mukherjee B, Patra B, Layek B, Mukherjee A. Sustained release of acyclovir from nano-liposomes and nano-niosomes: An in vitro study. Int J Nanomedicine. 2007 ;2(2): 213-25.

60. Maiti S, Paul S, Mondol R, Ray S, Sa B. Nanovesicular Formulation of Brimonidine Tartrate for the Management of Glaucoma: In Vitro and In Vivo Evaluation. AAPS PharmSciTech. 2011 ;12(2): 755-63.

61. Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, Jain NK. Micro-and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv. 2010; 7(7): 781-94.

62. Elhissi A, Hidayat K, Phoenix DA, Mwesigwa E, Crean S, Ahmed W, et al. Air-jet and vibrating-mesh nebulization of niosomes generated using a particulate-based proniosome technology. Int J Pharm. 2013 ;444: 193-9.

63. Priprem A, Limphirat W, Limsitthichaikoon S, Johns J, Mahakunakorn P. Intranasal Delivery of Nanosized Melatonin-Encapsulated Niosomes in Rats. . Open Access Sci Rep. 2012 ;1(4) :232-7.

64. Babu S, Fan C, Stepanskiy L, Uitto J, Papazoglou E. Effect of size at the nanoscale and bilayer rigidity on skin diffusion of liposomes. J Biomed Mat Res A. 2009 ;91(1): 140-8.

65. Alvi IA, Madan J, Kaushik D, Sardana S, Pandey RS, Ali A. Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis. Anticancer Drugs. 2011 ;22(8): 774-82.

66. Mali N, Darandale S, Vavia P. Niosomes as a vesicular carrier for topical administration of minoxidil: formulation and in vitro assessment. Drug Del Trans Res. 2012 :1-6.

67. Manosroi A, Khositsuntiwong N, Götz F, Werner RG, Manosroi J. Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic nanovesicles. J Liposome Res. 2009; 19(2): 91-8.

68. Honeywell-Nguyen PL, Bouwstra JA. The in vitro transport of pergolide from surfactant-based elastic vesicles through human skin: a suggested mechanism of action. J Control Release. 2003; 86(1) :145-56.

69. Ning M, Guo Y, Pan H, Yu H, Gu Z. Niosomes with sorbitan monoester as a carrier for vaginal delivery of insulin: Studies in rats. Drug Del. 2005; 12(6): 399-407.

70. Huang Y, Han G, Wang H, Liang W. Cationic niosomes as gene carriers: preparation and cellular uptake in vitro. Pharmazie. 2005 ;60: 473-4.

71. Meyer O, Kirpotin D, Hong K, Sternberg B, Park JW, Woodle MC, et al. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J Biol Chem. 1998 ;273(25): 15621-7.

72. Huang Y, Chen J, Chen X, Gao J, Liang W. PEGylated synthetic surfactant vesicles (Niosomes): novel carriers for oligonucleotides. J Mater Sci Mater Med. 2008; 19: 607-14.

73. Manosroi A, Thathang K, Werner R, Schubert R, Manosroi J. Stability of luciferase plasmid entrapped in cationic bilayer vesicles. Int J Pharm. 2008; 356: 291-9.

74. Manosroi A, Khositsuntiwong N, Götz F, Werner R, Manosroi J. Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic nanovesicles. J Liposome Res. 2009;19:91-8.

75. Manosroi J, Khositsuntiwong N, Manosroi W, Götz F, Werner R, Manosroi A. Enhancement of transdermal absorption, gene expression and stability of tyrosinase plasmid (pMEL34)-loaded elastic cationic niosomes: potential application in vitiligo treatment. J Pharm Sci. 2010 ;99: 3533-41.

76. Khositsuntiwong N, Manosroi A, Götz F, Werner RG, Manosroi W, Manosroi J. Enhancement of gene expression and melanin production of human tyrosinase gene loaded in elastic cationic niosomes. J Pharm Pharmacol. 2012.

77. Obrenovic MM, Perrie Y, Gregoriadis G. Entrapment of plasmid DNA into niosomes: characterization studies. J Pharm Pharmacol. 1998 ;50(S9):155-.

78. Brewer J, Alexander J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology. 1992; 75: 570-5.

79. Hassan Y, Brewer J, Alexander J, Jennings R. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems. Vaccine. 1996;14(17): 1581-9.

80. Mohamedi S, Brewer J, Alexander J, Heath A, Jennings R. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems. Vaccine. 2000;18(20):2083-94.

81. Yoshioka T, Skalko N, Gursel M, Gregoriadis G, Florence A. A non-ionic surfactant vesicle-in-water-in-oil (v/w/o) system: potential uses in drug and vaccine delivery. J Drug Target. 1995;2: 533-9.

82. Murdan S, Gregoriadis G, Florence A. Sorbitan monostearate/polysorbate 20 organogels containing niosomes: a delivery vehicle for antigens. Eur J Pharm Sci. 1999 ;8 : 77-86.

83. Chambers MA, Wright DC, Brisker J, Williams A, Hatch G, Gavier-Widén D, et al. A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis. Vaccine. 2004 ;22 (8): 1063-71.

84. Vangala A, Kirby D, Rosenkrands I, Agger E, Andersen P, Perrie Y. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. J pharm pharmacol. 2006; 58: 787-99.

85. cationicniosadjuvant2006.

86. Vangala A, Bramwell VW, McNeil S, Christensen D, Agger EM, Perrie Y. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J Control Release. 2007 ;119(1): 102-10.

87. Ferro V, Stimson W. Investigation into suitable carrier molecules for use in an anti-gonadotrophin releasing hormone vaccine. Vaccine. 1998; 16(11): 1095-102.

88. Ferro VA, Costa R, Carter KC, Harvey MJ, Waterston MM, Mullen AB, et al. Immune responses to a GnRH-based anti-fertility immunogen, induced by different adjuvants and subsequent effect on vaccine efficacy. Vaccine. 2004 ;22(8): 1024-31.

89. LezamaDávila CM. Vaccination of C57BL/10 mice against cutaneous leishmaniasis. Use of purified gp63 encapsulated into niosomes surfactants vesicles: a novel approach. Mem Inst Oswaldo Cruz. 1999; 94(1): 67-70.

90. Rentel C, Bouwstra J, Naisbett B, Junginger H. Niosomes as a novel peroral vaccine delivery system. Int J Pharm. 1999; 186: 161-7.

91. Chattaraj S, Das S. Physicochemical characterization of influenza viral vaccine loaded surfactant vesicles. Drug Del. 2003;10(2): 73-7.

92. Jain S, Vyas S. Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. J Liposome Res. 2006 ;16: 331-45.

93. Gupta P, Mishra V, Rawat A, Dubey P, Mahor S, Jain S, et al. Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm. 2005 ;293 :73-82.

94. Mahor S, Gupta PN, Rawat A, Vyas SP. A needle-free approach for topical immunization: antigen delivery via vesicular carrier system (s). Curr Med Chem. 2007 ;14(27): 2898-910.

95. Perrie Y, Barralet J, McNeil S, Vangala A. Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route. Int J Pharm.  2004; 284(1): 31-41.

96. Vyas S, Singh R, Jain S, Mishra V, Mahor S, Singh P, et al. Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm.  2005; 296: 80-6.